Publication | Closed Access

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial

Open-label Phase 2Gastrointestinal OncologyMedicineCancer ManagementGastroenterologyColorectal CancerPharmacotherapyCancer TreatmentOncologyRadiation Oncology